CytoDyn Inc. (CYDY)
CytoDyn Company Description
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.
The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.
The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Jacob Lalezari |
Contact Details
Address: 1111 Main Street Vancouver, Delaware 98660 United States | |
| Phone | 360 980 8524 |
| Website | cytodyn.com |
Stock Details
| Ticker Symbol | CYDY |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| ISIN Number | US23283M1018 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jacob P. Lalezari M.D. | Chief Executive Officer and Member of Scientific Advisory Board |
| Tyler Blok | Chief Legal Officer and Corporate Secretary |
| Dr. Cyrus Arman M.B.A., Ph.D. | Senior Vice President of Business Operations |
| Dr. Bernie Cunningham P.M.P., Ph.D. | Vice President of Operations |
| Dr. Scott Hansen Ph.D. | Head of Research and Basic Science |
| Dr. Max Lataillade D.O., M.P.H. | Senior Vice President and Head of Clinical Development |
| Cristina De Leon | Investors |